



McBryde, F., Hart, E., Ramchandra, R., & Paton, J. (2017). Evaluating the carotid bodies and renal nerves as therapeutic targets for hypertension. *Autonomic Neuroscience: Basic and Clinical*, 204, 126-130.  
<https://doi.org/10.1016/j.autneu.2016.08.002>

Peer reviewed version

Link to published version (if available):  
[10.1016/j.autneu.2016.08.002](https://doi.org/10.1016/j.autneu.2016.08.002)

[Link to publication record in Explore Bristol Research](#)  
PDF-document

This is the accepted author manuscript (AAM). The final published version (version of record) is available online via Elsevier at DOI:10.1016/j.autneu.2016.08.002. Please refer to any applicable terms of use of the publisher.

## **University of Bristol - Explore Bristol Research**

### **General rights**

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:  
<http://www.bristol.ac.uk/pure/about/ebr-terms>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

## Evaluating the carotid bodies and renal nerves as therapeutic targets for hypertension.

Fiona D. McBryde<sup>1,2</sup>, Emma C. Hart<sup>2</sup>, Rohit Ramchandra<sup>1</sup>, Julian F.R. Paton<sup>1,2</sup>

<sup>1</sup>Department of Physiology, Faculty of Medical and Health Sciences, University of Auckland, New Zealand

<sup>2</sup>School of Physiology, Pharmacology & Neuroscience, Biomedical Sciences, University of Bristol, Bristol, UK

### Abstract

Despite the plethora of current treatment options, hypertension remains a difficult condition to adequately control, and there is a pressing need for novel therapeutic strategies. The carotid body has recently become the focus of considerable interest as a potential novel treatment target in essential hypertension. Herein, we appraise the current literature suggesting that the carotid body plays an important causative role to generate sympathetic overactivity and drive increases in arterial pressure, in animal models of hypertension. We also review evidence from human studies showing cardiovascular benefits to the transient inactivation, or surgical removal of carotid bodies, and evaluate the potential benefits of pre-screening to identify patients likely to respond to carotid body-targeted therapy. Finally, given that a high proportion of patients who have undergone renal nerve ablation procedures remain hypertensive, we examine whether the renal nerves are necessary for the drop in blood pressure seen with carotid body removal.

**Key Words:** Renal Denervation, Carotid Body, Hypertension, Sympathetic Nervous System

1 High blood pressure is of pandemic proportions with between 25-33% of the world's population  
2 affected (Go et al., 2014). Its asymptomatic characteristic and multiple potential causes make this  
3 syndrome notoriously difficult to treat clinically. Interventions to control blood pressure are of high  
4 importance, as sustained hypertension is a major risk factor for stroke, heart disease, atherosclerosis  
5 and renal damage (Lewington et al., 2002). Here we compare interventional approaches for the  
6 treatment of hypertension with our focus on a novel anti-hypertensive target.

### 7 **Do we need new treatments for hypertension?**

8 Despite the armoury of anti-hypertensive medications currently available, only around 50% of  
9 treated patients have adequate blood pressure control (Go et al., 2014), an alarming statistic given  
10 that a 10mmHg rise in blood pressure doubles the risk of death from cardiovascular disease, and  
11 each 2 mmHg rise in blood pressure increases the risk of stroke by 10% (Lewington et al., 2002).  
12 Several possible factors may underpin this failure to control blood pressure, including white coat  
13 hypertension, sub-optimal treatment regimens and poor patient compliance. When other causes  
14 are excluded, true multi-drug resistant hypertension has been estimated to account for ~10% of all  
15 cases (de la Sierra et al., 2011; Persell, 2011). Poor adherence to anti-hypertensive medication is  
16 seen in a large proportion of patients – up to 40% of patients with newly diagnosed hypertension  
17 choose to discontinue their medication within 12 months (Mazzaglia et al., 2005), and 25% of  
18 patients enrolled into specialist hypertension clinics were non-adherent to treatment (Tomaszewski  
19 et al., 2014). This is undoubtedly related to the relatively high rate of side effects, which affect over  
20 one third of patients being treated for an otherwise largely asymptomatic condition (Benson et al.,  
21 2003). In order to address patient compliance, intolerance and drug-resistance, there is a pressing  
22 need for a wider range of treatment options to control blood pressure.

23 At present, pharmacological treatments for hypertension are dominated by drugs targeting the  
24 renin-angiotensin aldosterone system, such as ACE-inhibitors, angiotensin receptor blockers,  
25 diuretics and aldosterone antagonists targeting the mineralocorticoid receptor (Romero et al., 2015;  
26 Roush et al., 2016). In some countries,  $\beta$ -adrenoceptor blockers are prescribed to block  
27 sympathetically mediated release of renin from the kidney (Wong et al., 2016). Calcium channel  
28 blockers and  $\alpha_1$ -adrenoceptor antagonists reduce vascular resistance (Cubeddu, 1988; Tocci et al.,  
29 2015), while centrally-acting sympatholytic drugs such as the  $\alpha_2$ -adrenoceptor agonist clonidine and  
30 the imidazoline receptor agonist moxonidine, lower sympathetic activity (Sica, 2007). The clinician  
31 will typically follow a nationally-agreed protocol for drug type, dose and sequence/combinations  
32 (James et al., 2014; Mancia et al., 2007; Whitworth et al., 2003). In most cases blood pressure can be  
33 reduced, although not always to target levels (Go et al., 2014).

1 Aside from the release of the renin inhibitor aliskiren in 2007 (Brown, 2008), there have been no  
2 truly novel anti-hypertensive medications released in over 20 years. Instead, in recent years a series  
3 of device-based and surgical interventions have been trialled with varying degrees of success,  
4 including renal denervation (e.g. (Krum et al., 2009)), electrical stimulation of carotid baroreceptors  
5 (Heusser et al., 2010), deep brain stimulation (Patel et al., 2011) and arterial venous anastomosis  
6 (Lobo et al., 2015). For the treating physician, device-based or surgical approaches may offer a  
7 greater degree of control over patient compliance/intolerance when compared to conventional drug  
8 therapies.

### 9 **Current Problems with Renal Denervation**

10 Despite considerable promise in early studies (Esler et al., 2012; Krum et al., 2014), the recent  
11 SYMPLICITY HTN-3 trial has raised important questions about the broad use of renal denervation to  
12 treat essential hypertension (Bhatt et al., 2014). Since 2014, over 70 articles have been published  
13 discussing and debating the methods, design, results and implications of the SYMPLICITY trials. A  
14 particular problem is that when renal denervation is applied clinically to a diverse hypertensive  
15 cohort, the procedure only appears to benefit ~50% of patients (Brinkmann et al., 2012; Hart et al.,  
16 2013), and there is at present no clear process by which 'BP responders' can be pre-screened.  
17 Microneurography studies have suggested that muscle sympathetic nerve activity (SNA) tends to  
18 decrease after renal denervation, however both we and others have failed to find a correlation  
19 between either the baseline level or change in muscle SNA, and subsequent changes in blood  
20 pressure (Hart et al., 2013; Hering et al., 2014). Zuern *et al* found that cardiac baroreflex sensitivity  
21 could prospectively discriminate patients who would respond to renal denervation, although the  
22 degree of baroreflex impairment did not predict the size of the fall in blood pressure (Zuern et al.,  
23 2013). It has been recently suggested that the efficacy of renal denervation should be examined in  
24 different models of hypertension, as a way to match efficacy of procedure with causal mechanisms  
25 of the hypertension (Esler, 2015; Fink et al., 2014; Kandzari et al., 2015; Schlaich et al., 2014).  
26 Although small subgroups of patients have been shown to have a ~50% reduction in renal NE  
27 spillover after catheter ablation (Krum et al., 2009) , unfortunately there is currently no  
28 methodology that allows an easy routine assessment of the degree of renal nerve ablation achieved  
29 in the clinic, either on- or off- table. It is therefore difficult to reconcile the reported long-acting  
30 effects of renal denervation in human patients, with animal studies showing that functional afferent  
31 and efferent re-innervation of the kidney takes place in the months following renal denervation  
32 (Booth et al., 2015a; Booth et al., 2015b; Grisk et al., 2001; Mulder et al., 2013). Additionally, given  
33 that most antihypertensive drugs on the market already target renal mechanisms (see above), the

1 discovery of a truly novel therapeutic target would be appealing. Below, we discuss recent studies  
2 identifying the carotid body chemoreceptors as a putative target for antihypertensive treatment.

### 3 **Introducing the Carotid Body in Hypertension and Cardiovascular Disease**

4 We have recently proposed an afferent activation hypothesis for hypertension where hypoperfusion  
5 of an organ triggers sensory afferent discharge eliciting sympathoexcitation; the latter may worsen  
6 organ perfusion and positively feedback to further activate the afferent source (Koeners et al.,  
7 2016). One such organ considered is the carotid body. The carotid bodies are placed strategically at  
8 the carotid bifurcation to sample the composition of blood as it enters the brain, and act as  
9 guardians of cerebral perfusion (Ponte et al., 1974). The activation of the carotid bodies by hypoxia  
10 drives excitation in medullary pre-sympathetic pathways (Guyenet, 2000; King et al., 2012), giving  
11 rise to a sympathetically-mediated increase in arterial pressure, ultimately aimed at improving  
12 cerebral perfusion (Marshall, 1994; Narkiewicz et al., 2006; Paton et al., 2006; Somers et al., 1989).  
13 Interestingly, Ding *et al* have shown that the chronic partial occlusion of both carotid arteries results  
14 in a reduction in carotid body blood flow, an increase in resting renal SNA and hypersensitivity of the  
15 chemoreflex-mediated sympathetic response to hypoxia (Ding et al., 2011). This demonstrates that a  
16 prolonged challenge to carotid body and/or cerebral perfusion may drive a chronic increase in  
17 sympathetic outflow, although whether there was any concurrent impact on blood pressure in this  
18 model is not reported.

19 An extensive body of evidence published by ourselves and others demonstrates that the peripheral  
20 chemoreceptors show both hyper-sensitivity and aberrant tonicity in animal models of hypertension,  
21 activating the sympathetic nervous system and driving increases in arterial pressure. In the young  
22 spontaneously hypertensive rat, an increased sensitivity to chemoreceptor reflex stimulation is seen  
23 before the onset of hypertension (Tan et al., 2010), and transection of the carotid sinus nerve to  
24 disconnect the carotid bodies from the brain post-natally ameliorates the developmental rise in  
25 arterial pressure (Abdala et al., 2012), suggesting that peripheral chemoreceptor overactivity plays a  
26 causal role in the development of hypertension. In the adult spontaneously hypertensive rat rat, we  
27 have shown that carotid sinus nerve denervation produces a sustained fall in arterial pressure in  
28 conscious rats for many weeks (McBryde et al., 2013). These effects are rapid (2-3 days post-surgery)  
29 and are accompanied by a profound (50%) reduction in renal sympathetic nerve activity, improved  
30 baroreceptor reflex function and renal function, and reduced systemic inflammation (McBryde et al.,  
31 2013). Recently published work has identified a possible role of the carotid body in other forms of  
32 neurogenic hypertension, such as renovascular hypertension (Campos et al., 2015; Oliveira-Sales et  
33 al., 2016; Oliveira-Sales et al., 2014) and the hypertension induced by chronic intermittent hypoxia  
34 (Iturriaga et al., 2015; Marcus et al., 2010). Normotensive rats do not show a reduction in

1 sympathetic drive or arterial pressure after removal of carotid body input (McBryde et al., 2013),  
2 supporting the notion that aberrant chemoreflex activity is unique to the hypertensive setting. This  
3 is echoed in parallel human studies, where transient inactivation of the carotid bodies with  
4 hyperoxia caused a reduction in blood pressure in hypertensive, but not normotensive subjects  
5 (Sinski et al., 2014). The volume of the carotid bodies have been reported to be significantly larger in  
6 patients with essential hypertension (Heath et al., 1985), with size correlating with indirect measures  
7 of autonomic function (Jazwiec et al., 2015). Bilateral surgical resection of the carotid bodies to  
8 relieve symptoms in obstructive airway disease has been noted to reduce blood pressure acutely  
9 (Winter et al., 2004), with others observing that this effect persisted for at least 6 months in a  
10 hypertensive sub-group (Nakayama, 1961). A recent retrospective analysis of patients undergoing  
11 unilateral carotid body tumour removal, found sustained blood pressure reductions in 12 out of 20  
12 hypertensive patients (Fudim et al., 2015). Similarly, recent preliminary data from our research team  
13 shows that unilateral carotid body removal is associated with prolonged (12 month) reductions in  
14 arterial pressure and sympathetic activity, in ~60% of resistant hypertensive patients (Hart et al.,  
15 2016). While the proportion of resistant hypertensive patients who may benefit from carotid body  
16 ablation is similar to the ~50% of patients seen to respond to renal denervation, the ventilatory  
17 response to hypoxia appears to be a simple method able to discriminate responders from non-  
18 responders (Hart et al., 2016). Thus, unlike renal denervation, there is the potential to pre-screen for  
19 patients most likely to benefit from carotid body targeted treatment.

20 Taken together, these studies make a compelling case that the carotid bodies play a fundamental  
21 role in the pathogenesis of essential hypertension. Thus, exploiting the carotid bodies in order to  
22 reduce sympathetic overactivity in cardiovascular disease has attracted considerable scientific  
23 interest (Andrade et al., 2015; Kara et al., 2003; Niewinski et al., 2013; Paton et al., 2013a; Paton et  
24 al., 2013b; Ratcliffe et al., 2014; Schultz et al., 2015).

### 25 **Carotid body ablation after renal denervation**

26 Over 10'000 hypertensive patients worldwide have undergone renal denervation procedures, in  
27 many cases as a last resort after the failure of multi-drug therapy to control their blood pressure. If,  
28 as we propose, the carotid bodies are a viable therapeutic target for hypertension, is this of any  
29 relevance to the growing body of patients who have previously undergone renal denervation but  
30 remain hypertensive? We have shown that prior renal denervation does not attenuate the reduction  
31 in arterial pressure to carotid sinus nerve denervation in the spontaneously hypertensive rat (Figure  
32 1). This indicates that the presence of renal nerves is not required in order for the removal of carotid  
33 body input to have a beneficial effect on arterial pressure, supporting our notion of distinct afferent  
34 drives causing hypertension (Koeners et al. 2016). Importantly, the combined effect of severing

1 nerves to the kidneys and carotid bodies was additive. Thus, carotid body denervation could  
2 potentially provide therapeutic benefit in human hypertensive patients who have failed to respond  
3 to renal denervation.

#### 4 **Moving Forward**

5 Given the multi-factorial nature of essential hypertension, it is hardly surprising that optimizing  
6 patient treatment often requires an individualized, 'trial and error' approach, especially when our  
7 ability to phenotype symptoms remains so limited. However, it is apparent that new and effective  
8 interventional approaches are needed in some cases, to compliment current pharmacological  
9 treatment options. It will become essential to better diagnose the blood pressure controlling  
10 mechanisms in individuals in order to prescribe the most effective treatment strategy, whether  
11 pharmacological and/or interventional. Preclinical animal and a small number of human studies  
12 have confirmed the importance of the carotid bodies in mediating sympathetic overactivity and  
13 hypertension, and have built a strong case to investigate therapeutic targeting of carotid bodies in  
14 cardiovascular disease. To date, the only option to reduce carotid body activity long-term has been  
15 the surgical removal of one or both carotid bodies, although an ablation catheter is currently being  
16 trialled. While these procedures may have benefits in terms of guaranteeing patient compliance,  
17 approaches which do not permanently disable carotid body function may be more desirable in the  
18 long term. Thus, it may be attractive to also seek novel pharmacological compounds to selectively  
19 inhibit aberrant carotid body afferent signalling, while sparing its ability to respond to physiological  
20 cues. If proven to be successful, such a compound would be the first new class of anti-hypertensive  
21 drug in over 15 years.

22


#### 23 **Acknowledgements**

24 JFRP and ECH are supported by the British Heart Foundation (RG/12/6/29670; IBSRF FS/11/1/28400,  
25 respectively). FDM is funded by the Health Research Council of New Zealand (15/086 and 13/014)  
26 and the Royal Society Newton Fellow Scheme.

27

28

1



2

3 **Figure 1 – Prior Renal Denervation (RD) does not prevent the reduction of arterial blood pressure**  
 4 **with Carotid Sinus Denervation (CSD) in the spontaneously hypertensive rat.** Panel A: Systolic  
 5 blood pressure (SBP) before and after RD/sham, followed by CSD. Note the similar fall in SBP with  
 6 CSD, regardless of the presence or absence of renal nerves. Panel B: Change in SBP with combined  
 7 RD and CSD, compared to RD and CSD alone. The additive response regardless of whether CSD or RD  
 8 is performed first suggests an independent mechanism of action. Within-subject comparisons:  
 9 \* $p < 0.05$ , \*\* $p < 0.001$ , repeated measures ANOVA with Holm-Sidek posthoc comparisons: CSD vs RD  
 10 or sham. Between Group Comparisons: NS = not significant, # $p < 0.05$ , two way ANOVA with Holm-  
 11 Sidek posthoc comparisons: RD+CSD vs CSD+RD vs sham+CSD vs sham+RD. Redrawn from  
 12 (McBryde et al., 2013).



1 **References:**

- 2 Abdala, A.P., McBryde, F.D., Marina, N., Hendy, E.B., Engelman, Z.J., Fudim, M., Sobotka, P.A.,  
3 Gourine, A.V., Paton, J.F. 2012. Hypertension is critically dependent on the carotid body input in the  
4 spontaneously hypertensive rat. *J. Physiol.* 590, 4269-4277.
- 5 Andrade, D.C., Lucero, C., Toledo, C., Madrid, C., Marcus, N.J., Schultz, H.D., Del Rio, R. 2015.  
6 Relevance of the Carotid Body Chemoreflex in the Progression of Heart Failure. *BioMed research*  
7 *international* 2015, 467597.
- 8 Benson, J., Britten, N. 2003. Patients' views about taking antihypertensive drugs: questionnaire  
9 study. *BMJ* 326, 1314-1315.
- 10 Bhatt, D.L., Kandzari, D.E., O'Neill, W.W., D'Agostino, R., Flack, J.M., Katzen, B.T., Leon, M.B., Liu, M.,  
11 Mauri, L., Negoita, M., Cohen, S.A., Oparil, S., Rocha-Singh, K., Townsend, R.R., Bakris, G.L.,  
12 Investigators, S.H.-. 2014. A controlled trial of renal denervation for resistant hypertension. *N. Engl.*  
13 *J. Med.* 370, 1393-1401.
- 14 Booth, L.C., Nishi, E.E., Yao, S.T., Ramchandra, R., Lambert, G.W., Schlaich, M.P., May, C.N. 2015a.  
15 Reinnervation following catheter-based radio-frequency renal denervation. *Exp. Physiol.* 100, 485-  
16 490.
- 17 Booth, L.C., Nishi, E.E., Yao, S.T., Ramchandra, R., Lambert, G.W., Schlaich, M.P., May, C.N. 2015b.  
18 Reinnervation of renal afferent and efferent nerves at 5.5 and 11 months after catheter-based  
19 radiofrequency renal denervation in sheep. *Hypertension* 65, 393-400.
- 20 Brinkmann, J., Heusser, K., Schmidt, B.M., Menne, J., Klein, G., Bauersachs, J., Haller, H., Sweep, F.C.,  
21 Diedrich, A., Jordan, J., Tank, J. 2012. Catheter-based renal nerve ablation and centrally generated  
22 sympathetic activity in difficult-to-control hypertensive patients: prospective case series.  
23 *Hypertension* 60, 1485-1490.
- 24 Brown, M.J. 2008. Aliskiren. *Circulation* 118, 773-784.
- 25 Campos, R.R., Oliveira-Sales, E.B., Nishi, E.E., Paton, J.F., Bergamaschi, C.T. 2015. Mechanisms of  
26 renal sympathetic activation in renovascular hypertension. *Exp. Physiol.* 100, 496-501.
- 27 Cubeddu, L.X. 1988. New alpha 1-adrenergic receptor antagonists for the treatment of hypertension:  
28 role of vascular alpha receptors in the control of peripheral resistance. *Am. Heart J.* 116, 133-162.
- 29 de la Sierra, A., Segura, J., Banegas, J.R., Gorostidi, M., de la Cruz, J.J., Armario, P., Oliveras, A.,  
30 Ruilope, L.M. 2011. Clinical features of 8295 patients with resistant hypertension classified on the  
31 basis of ambulatory blood pressure monitoring. *Hypertension* 57, 898-902.
- 32 Ding, Y., Li, Y.L., Schultz, H.D. 2011. Role of blood flow in carotid body chemoreflex function in heart  
33 failure. *J. Physiol.* 589, 245-258.
- 34 Esler, M. 2015. Renal denervation for treatment of drug-resistant hypertension. *Trends Cardiovasc.*  
35 *Med.* 25, 107-115.
- 36 Esler, M.D., Krum, H., Schlaich, M., Schmieder, R.E., Bohm, M., Sobotka, P.A., Symplicity, H.T.N.I.  
37 2012. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results  
38 from the Symplicity HTN-2 randomized, controlled trial. *Circulation* 126, 2976-2982.
- 39 Fink, G.D., Osborn, J.W. 2014. Renal nerves: time for reassessment of their role in hypertension? *Am.*  
40 *J. Hypertens.* 27, 1245-1247.
- 41 Fudim, M., Groom, K.L., Laffer, C.L., Netterville, J.L., Robertson, D., Elijovich, F. 2015. Effects of  
42 carotid body tumor resection on the blood pressure of essential hypertensive patients. *J. Am. Soc.*  
43 *Hypertens.* 9, 435-442.
- 44 Go, A.S., Mozaffarian, D., Roger, V.L., Benjamin, E.J., Berry, J.D., Blaha, M.J., Dai, S., Ford, E.S., Fox,  
45 C.S., Franco, S., Fullerton, H.J., Gillespie, C., Hailpern, S.M., Heit, J.A., Howard, V.J., Huffman, M.D.,  
46 Judd, S.E., Kissela, B.M., Kittner, S.J., Lackland, D.T., Lichtman, J.H., Lisabeth, L.D., Mackey, R.H.,  
47 Magid, D.J., Marcus, G.M., Marelli, A., Matchar, D.B., McGuire, D.K., Mohler, E.R., 3rd, Moy, C.S.,  
48 Mussolino, M.E., Neumar, R.W., Nichol, G., Pandey, D.K., Paynter, N.P., Reeves, M.J., Sorlie, P.D.,  
49 Stein, J., Towfighi, A., Turan, T.N., Virani, S.S., Wong, N.D., Woo, D., Turner, M.B., American Heart  
50 Association Statistics, C., Stroke Statistics, S. 2014. Executive summary: heart disease and stroke  
51 statistics--2014 update: a report from the American Heart Association. *Circulation* 129, 399-410.

- 1 Grisk, O., Grone, H.J., Rose, H.J., Rettig, R. 2001. Sympathetic reinnervation of rat kidney grafts.  
2 Transplantation 72, 1153-1155.
- 3 Guyenet, P.G. 2000. Neural structures that mediate sympathoexcitation during hypoxia. *Respir.*  
4 *Physiol.* 121, 147-162.
- 5 Hart, E.C., McBryde, F.D., Burchell, A.E., Ratcliffe, L.E., Stewart, L.Q., Baumbach, A., Nightingale, A.,  
6 Paton, J.F. 2013. Translational examination of changes in baroreflex function after renal denervation  
7 in hypertensive rats and humans. *Hypertension* 62, 533-541.
- 8 Hart, E.C., Ratcliffe, L.E.K., Krzysztof Narkiewicz, K., Briant, J., Chrostowska, M., Wolf, J., Szyndler, A.,  
9 Hering, D., Burchell, A., Abdala, A., Durant, C., Lobo, M., Sobotka, P., Patel, N., Leiter, J., Engelman,  
10 Z., Nightingale, A., Paton, J. 2016. Unilateral carotid body resection in patients with resistant  
11 hypertension: a safety and feasibility trial. *FASEBJ* 30, 1286.1284.
- 12 Heath, D., Smith, P., Fitch, R., Harris, P. 1985. Comparative pathology of the enlarged carotid body. *J.*  
13 *Comp. Pathol.* 95, 259-271.
- 14 Hering, D., Marusic, P., Walton, A.S., Lambert, E.A., Krum, H., Narkiewicz, K., Lambert, G.W., Esler,  
15 M.D., Schlaich, M.P. 2014. Sustained sympathetic and blood pressure reduction 1 year after renal  
16 denervation in patients with resistant hypertension. *Hypertension* 64, 118-124.
- 17 Heusser, K., Tank, J., Engeli, S., Diedrich, A., Menne, J., Eckert, S., Peters, T., Sweep, F.C., Haller, H.,  
18 Pichlmaier, A.M., Luft, F.C., Jordan, J. 2010. Carotid baroreceptor stimulation, sympathetic activity,  
19 baroreflex function, and blood pressure in hypertensive patients. *Hypertension* 55, 619-626.
- 20 Iturriaga, R., Andrade, D.C., Del Rio, R. 2015. Crucial Role of the Carotid Body Chemoreceptors on the  
21 Development of High Arterial Blood Pressure During Chronic Intermittent Hypoxia. *Adv. Exp. Med.*  
22 *Biol.* 860, 255-260.
- 23 James, P.A., Oparil, S., Carter, B.L., Cushman, W.C., Dennison-Himmelfarb, C., Handler, J., Lackland,  
24 D.T., LeFevre, M.L., MacKenzie, T.D., Ogedegbe, O., Smith, S.C., Jr., Svetkey, L.P., Taler, S.J.,  
25 Townsend, R.R., Wright, J.T., Jr., Narva, A.S., Ortiz, E. 2014. 2014 evidence-based guideline for the  
26 management of high blood pressure in adults: report from the panel members appointed to the  
27 Eighth Joint National Committee (JNC 8). *JAMA* 311, 507-520.
- 28 Jazwiec, P., Gac, P., Jurdzia, M., Poreba, M., Mazur, G., Sobieszczanska, M., Poreba, R. 2015.  
29 Volume of carotid bodies and cardiac autonomic function in patients with essential hypertension.  
30 *Auton. Neurosci.* 190, 26-32.
- 31 Kandzari, D.E., Bhatt, D.L., Brar, S., Devireddy, C.M., Esler, M., Fahy, M., Flack, J.M., Katzen, B.T., Lea,  
32 J., Lee, D.P., Leon, M.B., Ma, A., Massaro, J., Mauri, L., Oparil, S., O'Neill, W.W., Patel, M.R., Rocha-  
33 Singh, K., Sobotka, P.A., Svetkey, L., Townsend, R.R., Bakris, G.L. 2015. Predictors of blood pressure  
34 response in the SYMPLICITY HTN-3 trial. *Eur. Heart J.* 36, 219-227.
- 35 Kara, T., Narkiewicz, K., Somers, V.K. 2003. Chemoreflexes--physiology and clinical implications. *Acta*  
36 *Physiol. Scand.* 177, 377-384.
- 37 King, T.L., Heesch, C.M., Clark, C.G., Kline, D.D., Hasser, E.M. 2012. Hypoxia activates nucleus tractus  
38 solitarius neurons projecting to the paraventricular nucleus of the hypothalamus. *Am. J. Physiol.*  
39 *Regul. Integr. Comp. Physiol.* 302, R1219-1232.
- 40 Koeners, M.P., Lewis, K.E., Ford, A.P., Paton, J.F. 2016. Hypertension: a problem of organ blood flow  
41 supply-demand mismatch. *Future Cardiol.*
- 42 Krum, H., Schlaich, M., Whitbourn, R., Sobotka, P.A., Sadowski, J., Bartus, K., Kapelak, B., Walton, A.,  
43 Sievert, H., Thambar, S., Abraham, W.T., Esler, M. 2009. Catheter-based renal sympathetic  
44 denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.  
45 *Lancet* 373, 1275-1281.
- 46 Krum, H., Schlaich, M.P., Sobotka, P.A., Bohm, M., Mahfoud, F., Rocha-Singh, K., Katholi, R., Esler,  
47 M.D. 2014. Percutaneous renal denervation in patients with treatment-resistant hypertension: final  
48 3-year report of the Symplicity HTN-1 study. *Lancet* 383, 622-629.
- 49 Lewington, S., Clarke, R., Qizilbash, N., Peto, R., Collins, R., Prospective Studies, C. 2002. Age-specific  
50 relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one  
51 million adults in 61 prospective studies. *Lancet* 360, 1903-1913.

- 1 Lobo, M.D., Sobotka, P.A., Stanton, A., Cockcroft, J.R., Sulke, N., Dolan, E., van der Giet, M., Hoyer, J.,  
 2 Furniss, S.S., Foran, J.P., Witkowski, A., Januszewicz, A., Schoors, D., Tsioufis, K., Rensing, B.J., Scott,  
 3 B., Ng, G.A., Ott, C., Schmieder, R.E., Investigators, R.C.H. 2015. Central arteriovenous anastomosis  
 4 for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a  
 5 randomised controlled trial. *Lancet* 385, 1634-1641.
- 6 Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty,  
 7 A.M., Kjeldsen, S.E., Laurent, S., Narkiewicz, K., Ruilope, L., Rynkiewicz, A., Schmieder, R.E., Struijker  
 8 Boudier, H.A., Zanchetti, A., Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K.,  
 9 Filippatos, G., Funck-Brentano, C., Hellemans, I., Kristensen, S.D., McGregor, K., Sechtem, U., Silber,  
 10 S., Tendera, M., Widimsky, P., Zamorano, J.L., Kjeldsen, S.E., Erdine, S., Narkiewicz, K., Kiowski, W.,  
 11 Agabiti-Rosei, E., Ambrosioni, E., Cifkova, R., Dominiczak, A., Fagard, R., Heagerty, A.M., Laurent, S.,  
 12 Lindholm, L.H., Mancia, G., Manolis, A., Nilsson, P.M., Redon, J., Schmieder, R.E., Struijker-Boudier,  
 13 H.A., Viigimaa, M., Filippatos, G., Adamopoulos, S., Agabiti-Rosei, E., Ambrosioni, E., Bertomeu, V.,  
 14 Clement, D., Erdine, S., Farsang, C., Gaita, D., Kiowski, W., Lip, G., Mallion, J.M., Manolis, A.J.,  
 15 Nilsson, P.M., O'Brien, E., Ponikowski, P., Redon, J., Ruschitzka, F., Tamargo, J., van Zwieten, P.,  
 16 Viigimaa, M., Waeber, B., Williams, B., Zamorano, J.L., The task force for the management of arterial  
 17 hypertension of the European Society of, H., The task force for the management of arterial  
 18 hypertension of the European Society of, C. 2007. 2007 Guidelines for the management of arterial  
 19 hypertension: The Task Force for the Management of Arterial Hypertension of the European Society  
 20 of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur. Heart J.* 28, 1462-1536.
- 21 Marcus, N.J., Li, Y.L., Bird, C.E., Schultz, H.D., Morgan, B.J. 2010. Chronic intermittent hypoxia  
 22 augments chemoreflex control of sympathetic activity: role of the angiotensin II type 1 receptor.  
 23 *Respir. Physiol. Neurobiol.* 171, 36-45.
- 24 Marshall, J.M. 1994. Peripheral chemoreceptors and cardiovascular regulation. *Physiol. Rev.* 74, 543-  
 25 594.
- 26 Mazzaglia, G., Mantovani, L.G., Sturkenboom, M.C., Filippi, A., Trifiro, G., Cricelli, C., Brignoli, O.,  
 27 Caputi, A.P. 2005. Patterns of persistence with antihypertensive medications in newly diagnosed  
 28 hypertensive patients in Italy: a retrospective cohort study in primary care. *J. Hypertens.* 23, 2093-  
 29 2100.
- 30 McBryde, F.D., Abdala, A.P., Hendy, E.B., Pijacka, W., Marvar, P., Moraes, D.J., Sobotka, P.A., Paton,  
 31 J.F. 2013. The carotid body as a putative therapeutic target for the treatment of neurogenic  
 32 hypertension. *Nat Commun* 4, 2395.
- 33 Mulder, J., Hokfelt, T., Knuepfer, M.M., Kopp, U.C. 2013. Renal sensory and sympathetic nerves  
 34 reinnervate the kidney in a similar time-dependent fashion after renal denervation in rats. *Am. J.*  
 35 *Physiol. Regul. Integr. Comp. Physiol.* 304, R675-682.
- 36 Nakayama, K. 1961. Surgical removal of the carotid body for bronchial asthma. *Dis. Chest* 40, 595-  
 37 604.
- 38 Narkiewicz, K., van de Borne, P., Montano, N., Hering, D., Kara, T., Somers, V.K. 2006. Sympathetic  
 39 neural outflow and chemoreflex sensitivity are related to spontaneous breathing rate in normal  
 40 men. *Hypertension* 47, 51-55.
- 41 Niewinski, P., Janczak, D., Rucinski, A., Jazwiec, P., Sobotka, P.A., Engelman, Z.J., Fudim, M., Tubek,  
 42 S., Jankowska, E.A., Banasiak, W., Hart, E.C., Paton, J.F., Ponikowski, P. 2013. Carotid body removal  
 43 for treatment of chronic systolic heart failure. *Int. J. Cardiol.* 168, 2506-2509.
- 44 Oliveira-Sales, E.B., Colombari, E., Abdala, A.P., Campos, R.R., Paton, J.F. 2016. Sympathetic  
 45 overactivity occurs before hypertension in the two-kidney, one-clip model. *Exp. Physiol.* 101, 67-80.
- 46 Oliveira-Sales, E.B., Toward, M.A., Campos, R.R., Paton, J.F. 2014. Revealing the role of the  
 47 autonomic nervous system in the development and maintenance of Goldblatt hypertension in rats.  
 48 *Auton. Neurosci.* 183, 23-29.
- 49 Patel, N.K., Javed, S., Khan, S., Papouchado, M., Malizia, A.L., Pickering, A.E., Paton, J.F. 2011. Deep  
 50 brain stimulation relieves refractory hypertension. *Neurology* 76, 405-407.

- 1 Paton, J.F., Nalivaiko, E., Boscan, P., Pickering, A.E. 2006. Reflexly evoked coactivation of cardiac  
2 vagal and sympathetic motor outflows: observations and functional implications. *Clin. Exp.*  
3 *Pharmacol. Physiol.* 33, 1245-1250.
- 4 Paton, J.F., Ratcliffe, L., Hering, D., Wolf, J., Sobotka, P.A., Narkiewicz, K. 2013a. Revelations about  
5 carotid body function through its pathological role in resistant hypertension. *Curr. Hypertens. Rep.*  
6 15, 273-280.
- 7 Paton, J.F., Sobotka, P.A., Fudim, M., Engelman, Z.J., Hart, E.C., McBryde, F.D., Abdala, A.P., Marina,  
8 N., Gourine, A.V., Lobo, M., Patel, N., Burchell, A., Ratcliffe, L., Nightingale, A. 2013b. The carotid  
9 body as a therapeutic target for the treatment of sympathetically mediated diseases. *Hypertension*  
10 61, 5-13.
- 11 Persell, S.D. 2011. Prevalence of resistant hypertension in the United States, 2003-2008.  
12 *Hypertension* 57, 1076-1080.
- 13 Ponte, J., Purves, M.J. 1974. The role of the carotid body chemoreceptors and carotid sinus  
14 baroreceptors in the control of cerebral blood vessels. *J. Physiol.* 237, 315-340.
- 15 Ratcliffe, L.E., Pijacka, W., McBryde, F.D., Abdala, A.P., Moraes, D.J., Sobotka, P.A., Hart, E.C.,  
16 Narkiewicz, K., Nightingale, A.K., Paton, J.F. 2014. CrossTalk opposing view: Which technique for  
17 controlling resistant hypertension? Carotid chemoreceptor denervation/modulation. *J. Physiol.* 592,  
18 3941-3944.
- 19 Romero, C.A., Orias, M., Weir, M.R. 2015. Novel RAAS agonists and antagonists: clinical applications  
20 and controversies. *Nat. Rev. Endocrinol.* 11, 242-252.
- 21 Roush, G.C., Sica, D.A. 2016. Diuretics for Hypertension: A Review and Update. *Am. J. Hypertens.*
- 22 Schlaich, M.P., Esler, M.D., Fink, G.D., Osborn, J.W., Euler, D.E. 2014. Targeting the sympathetic  
23 nervous system: critical issues in patient selection, efficacy, and safety of renal denervation.  
24 *Hypertension* 63, 426-432.
- 25 Schultz, H.D., Marcus, N.J., Del Rio, R. 2015. Role of the Carotid Body Chemoreflex in the  
26 Pathophysiology of Heart Failure: A Perspective from Animal Studies. *Adv. Exp. Med. Biol.* 860, 167-  
27 185.
- 28 Sica, D.A. 2007. Centrally acting antihypertensive agents: an update. *J. Clin. Hypertens. (Greenwich)*  
29 9, 399-405.
- 30 Sinski, M., Lewandowski, J., Przybylski, J., Zalewski, P., Symonides, B., Abramczyk, P., Gaciong, Z.  
31 2014. Deactivation of carotid body chemoreceptors by hyperoxia decreases blood pressure in  
32 hypertensive patients. *Hypertens. Res.* 37, 858-862.
- 33 Somers, V.K., Mark, A.L., Zavala, D.C., Abboud, F.M. 1989. Contrasting effects of hypoxia and  
34 hypercapnia on ventilation and sympathetic activity in humans. *J Appl Physiol* (1985) 67, 2101-2106.
- 35 Tan, Z.Y., Lu, Y., Whiteis, C.A., Simms, A.E., Paton, J.F., Chappleau, M.W., Abboud, F.M. 2010.  
36 Chemoreceptor hypersensitivity, sympathetic excitation, and overexpression of ASIC and TASK  
37 channels before the onset of hypertension in SHR. *Circ. Res.* 106, 536-545.
- 38 Tocci, G., Battistoni, A., Passerini, J., Musumeci, M.B., Francia, P., Ferrucci, A., Volpe, M. 2015.  
39 Calcium channel blockers and hypertension. *J. Cardiovasc. Pharmacol. Ther.* 20, 121-130.
- 40 Tomaszewski, M., White, C., Patel, P., Masca, N., Damani, R., Hepworth, J., Samani, N.J., Gupta, P.,  
41 Madira, W., Stanley, A., Williams, B. 2014. High rates of non-adherence to antihypertensive  
42 treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-  
43 MS/MS) urine analysis. *Heart* 100, 855-861.
- 44 Whitworth, J.A., World Health Organization, I.S.o.H.W.G. 2003. 2003 World Health Organization  
45 (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. *J.*  
46 *Hypertens.* 21, 1983-1992.
- 47 Winter, B., Whipp, B.J. 2004. Immediate effects of bilateral carotid body resection on total  
48 respiratory resistance and compliance in humans. *Adv. Exp. Med. Biol.* 551, 15-21.
- 49 Wong, G.W., Boyda, H.N., Wright, J.M. 2016. Blood pressure lowering efficacy of beta-1 selective  
50 beta blockers for primary hypertension. *The Cochrane database of systematic reviews* 3, CD007451.

- 1 Zuern, C.S., Eick, C., Rizas, K.D., Bauer, S., Langer, H., Gawaz, M., Bauer, A. 2013. Impaired cardiac
- 2 baroreflex sensitivity predicts response to renal sympathetic denervation in patients with resistant
- 3 hypertension. *J. Am. Coll. Cardiol.* 62, 2124-2130.

4